TherapeuticsMD Company Profile (NASDAQ:TXMD)

About TherapeuticsMD (NASDAQ:TXMD)

TherapeuticsMD logoTherapeuticsMD, Inc. is a women's healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort. With its SYMBODA technology, it is developing hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through dosage forms and administration routes. Its product line includes vitaTrue, vitaPearl, vitaMedMD Plus, vitaMedMD One Prenatal Multivitamin, vitaMedMD Plus Rx Prenatal Multivitamin, vitaMedMD One Rx Prenatal Multivitamin, vitaMedMD Iron 21/7, vitaMedMD Vitamin D3 50,000 IU, BocaGreenMD Prena1 Pearl and BocaGreenMD Prena1 Chew.

Industry, Sector and Symbol: Capitalization:
  • Market Cap: $1.1 billion
  • Outstanding Shares: 203,927,000
Average Prices:
  • 50 Day Moving Avg: $5.04
  • 200 Day Moving Avg: $5.56
  • 52 Week Range: $3.50 - $8.30
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -53.70
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $18.41 million
  • Price / Sales: 59.48
  • Book Value: $0.56 per share
  • Price / Book: 9.59
Profitability:
  • EBIDTA: ($90,400,000.00)
  • Net Margins: -530.84%
  • Return on Equity: -71.36%
  • Return on Assets: -63.59%
Misc:
  • Average Volume: 2.84 million shs.
  • Short Ratio: 19.16
 

Frequently Asked Questions for TherapeuticsMD (NASDAQ:TXMD)

What is TherapeuticsMD's stock symbol?

TherapeuticsMD trades on the NASDAQ under the ticker symbol "TXMD."

When will TherapeuticsMD make its next earnings announcement?

TherapeuticsMD is scheduled to release their next quarterly earnings announcement on Thursday, August, 3rd 2017. View Earnings Estimates for TherapeuticsMD.

Where is TherapeuticsMD's stock going? Where will TherapeuticsMD's stock price be in 2017?

7 analysts have issued 12-month price objectives for TherapeuticsMD's stock. Their forecasts range from $10.00 to $33.00. On average, they anticipate TherapeuticsMD's stock price to reach $16.14 in the next year. View Analyst Ratings for TherapeuticsMD.

Who are some of TherapeuticsMD's key competitors?

Who are TherapeuticsMD's key executives?

TherapeuticsMD's management team includes the folowing people:

  • Tommy G. Thompson J.D., Independent Chairman of the Board
  • John C. K. Milligan IV, President, Secretary, Director
  • Robert G. Finizio, Chief Executive Officer, Director
  • Daniel A. Cartwright, Chief Financial Officer, Treasurer
  • Mitchell L. Krassan, Executive Vice President, Chief Strategy Officer
  • Michael Donegan, Vice President - Finance
  • Brian Bernick M.D., Chief Clinical Officer, Director
  • Jules A. Musing, Director
  • J. Martin Carroll, Independent Director
  • Cooper C. Collins, Independent Director

Who owns TherapeuticsMD stock?

TherapeuticsMD's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Sanders Morris Harris LLC (0.28%), Capital Impact Advisors LLC (0.06%), Bank of Montreal Can (0.04%) and Aperio Group LLC (0.02%). View Institutional Ownership Trends for TherapeuticsMD.

Who sold TherapeuticsMD stock? Who is selling TherapeuticsMD stock?

TherapeuticsMD's stock was sold by a variety of institutional investors in the last quarter, including Capital Impact Advisors LLC, Bank of Montreal Can and Aperio Group LLC. View Insider Buying and Selling for TherapeuticsMD.

Who bought TherapeuticsMD stock? Who is buying TherapeuticsMD stock?

TherapeuticsMD's stock was purchased by a variety of institutional investors in the last quarter, including Sanders Morris Harris LLC. View Insider Buying and Selling for TherapeuticsMD.

How do I buy TherapeuticsMD stock?

Shares of TherapeuticsMD can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is TherapeuticsMD's stock price today?

One share of TherapeuticsMD stock can currently be purchased for approximately $5.37.


MarketBeat Community Rating for TherapeuticsMD (NASDAQ TXMD)
Community Ranking:  2.4 out of 5 ( )
Outperform Votes:  31 (Vote Outperform)
Underperform Votes:  33 (Vote Underperform)
Total Votes:  64
MarketBeat's community ratings are surveys of what our community members think about TherapeuticsMD and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for TherapeuticsMD (NASDAQ:TXMD) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 7 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $16.14 (200.61% upside)

Analysts' Ratings History for TherapeuticsMD (NASDAQ:TXMD)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/21/2017Cantor FitzgeraldReiterated RatingOverweight$33.00LowView Rating Details
7/21/2017Deutsche Bank AGInitiated CoverageBuy$10.00MediumView Rating Details
7/17/2017Cowen and CompanyReiterated RatingOutperform$13.00LowView Rating Details
7/11/2017CIBCUpgradeMarket Perform -> OutperformHighView Rating Details
7/11/2017Oppenheimer Holdings, Inc.UpgradeMarket Perform -> Outperform$10.00HighView Rating Details
6/14/2017Jefferies Group LLCSet Price TargetBuy$15.00HighView Rating Details
5/24/2017Stifel NicolausReiterated RatingBuy$20.00HighView Rating Details
(Data available from 7/21/2015 forward)

Earnings

Earnings History for TherapeuticsMD (NASDAQ:TXMD)
Earnings by Quarter for TherapeuticsMD (NASDAQ:TXMD)
Earnings History by Quarter for TherapeuticsMD (NASDAQ TXMD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/2/2017($0.11)N/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for TherapeuticsMD (NASDAQ:TXMD)
Current Year EPS Consensus Estimate: $-0.45 EPS
Next Year EPS Consensus Estimate: $-0.10 EPS

Dividends

Dividend History for TherapeuticsMD (NASDAQ:TXMD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for TherapeuticsMD (NASDAQ:TXMD)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for TherapeuticsMD (NASDAQ:TXMD)
Latest Headlines for TherapeuticsMD (NASDAQ:TXMD)
Source:
DateHeadline
americanbankingnews.com logoCowen and Company Reiterates Outperform Rating for TherapeuticsMD Inc (TXMD)
www.americanbankingnews.com - July 17 at 10:20 PM
fool.com logoWhy TherapeuticsMD Inc Is Getting Clobbered
www.fool.com - July 17 at 12:46 PM
americanbankingnews.com logoCIBC Upgrades TherapeuticsMD Inc (TXMD) to Outperform
www.americanbankingnews.com - July 11 at 2:58 PM
americanbankingnews.com logoTherapeuticsMD Inc (TXMD) Lifted to Outperform at Oppenheimer Holdings, Inc.
www.americanbankingnews.com - July 11 at 10:43 AM
americanbankingnews.com logoTherapeuticsMD Inc (NASDAQ:TXMD) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - July 11 at 10:06 AM
americanbankingnews.com logoTherapeuticsMD Target of Unusually Large Options Trading (TXMD)
www.americanbankingnews.com - July 9 at 7:08 AM
seekingalpha.com logoProfit From TherapeuticsMD's Upcoming FDA Catalyst
seekingalpha.com - July 6 at 2:53 PM
americanbankingnews.com logo$4.95 Million in Sales Expected for TherapeuticsMD Inc (TXMD) This Quarter
www.americanbankingnews.com - July 1 at 9:54 AM
americanbankingnews.com logo Analysts Anticipate TherapeuticsMD Inc (TXMD) Will Announce Earnings of -$0.10 Per Share
www.americanbankingnews.com - June 29 at 7:48 AM
americanbankingnews.com logoTherapeuticsMD (TXMD) & Check-Cap (CHEK) Financial Analysis
www.americanbankingnews.com - June 18 at 6:02 PM
americanbankingnews.com logoTherapeuticsMD Inc (TXMD) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - June 15 at 4:36 PM
finance.yahoo.com logoEQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of a Class Action to Recover Losses Suffered by Investors in TherapeuticsMD, Inc.
finance.yahoo.com - June 15 at 3:41 PM
finance.yahoo.com logoMONDAY DEADLINE: Lundin Law PC Announces a Securities Class Action Lawsuit against TherapeuticsMD, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - June 15 at 3:41 PM
americanbankingnews.com logoAnalysts Anticipate TherapeuticsMD Inc (TXMD) to Post ($0.10) EPS
www.americanbankingnews.com - June 15 at 2:52 PM
americanbankingnews.com logoTherapeuticsMD Inc (TXMD) Given a $15.00 Price Target at Jefferies Group LLC
www.americanbankingnews.com - June 15 at 2:32 PM
finance.yahoo.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of a Class Action to Recover Losses Suffered by Investors in TherapeuticsMD, Inc. and a Lead Plaintiff Deadline of June 19, 2017 - TXMD
finance.yahoo.com - June 8 at 1:34 AM
finance.yahoo.com logoDEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against TherapeuticsMD, Inc. (TXMD) and Lead Plaintiff Deadline - June 19, 2017
finance.yahoo.com - June 8 at 1:34 AM
finance.yahoo.com logoAPPROACHING DEADLINE: Lundin Law PC Announces a Securities Class Action Lawsuit against TherapeuticsMD, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - June 8 at 1:34 AM
americanbankingnews.com logoTherapeuticsMD Inc (TXMD) Expected to Announce Quarterly Sales of $4.95 Million
www.americanbankingnews.com - June 7 at 1:06 PM
americanbankingnews.com logo Analysts Expect TherapeuticsMD Inc (TXMD) Will Post Earnings of -$0.10 Per Share
www.americanbankingnews.com - June 5 at 8:04 AM
americanbankingnews.com logoZacks: TherapeuticsMD Inc (TXMD) Receives Consensus Recommendation of "Strong Buy" from Analysts
www.americanbankingnews.com - May 26 at 2:32 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against TherapeuticsMD, Inc. (TXMD) and Lead Plaintiff Deadline: June 19, 2017
finance.yahoo.com - May 25 at 5:54 AM
finance.yahoo.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of a Complaint to Recover Losses Suffered by Investors in TherapeuticsMD, Inc. - Sets Lead Plaintiff Deadline of June 19, 2017 - TXMD
finance.yahoo.com - May 25 at 5:54 AM
finance.yahoo.com logoIMPORTANT THERAPEUTICSMD, INC. INVESTOR REMINDER: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of Florida against TherapeuticsMD, Inc.
finance.yahoo.com - May 25 at 5:54 AM
americanbankingnews.com logoTherapeuticsMD's (TXMD) Buy Rating Reaffirmed at Stifel Nicolaus
www.americanbankingnews.com - May 24 at 10:18 PM
americanbankingnews.com logoTherapeuticsMD Inc (TXMD) Upgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - May 12 at 11:56 PM
americanbankingnews.com logoTherapeuticsMD Inc (TXMD) Expected to Post Quarterly Sales of $4.95 Million
www.americanbankingnews.com - May 11 at 11:00 AM
bizjournals.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TherapeuticsMD, Inc. - TXMD
www.bizjournals.com - May 11 at 2:32 AM
finance.yahoo.com logoINVESTOR ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against TherapeuticsMD, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - May 11 at 2:32 AM
finance.yahoo.com logoTherapeuticsMD Announces Presentation at Bank of America Merrill Lynch 2017 Healthcare Conference on May 16
finance.yahoo.com - May 11 at 2:32 AM
americanbankingnews.com logoCantor Fitzgerald Reaffirms "Overweight" Rating for TherapeuticsMD Inc (TXMD)
www.americanbankingnews.com - May 10 at 9:58 AM
americanbankingnews.com logoZacks: TherapeuticsMD Inc (TXMD) Receives Average Rating of "Strong Buy" from Analysts
www.americanbankingnews.com - May 9 at 6:38 PM
americanbankingnews.com logo-$0.10 Earnings Per Share Expected for TherapeuticsMD Inc (TXMD) This Quarter
www.americanbankingnews.com - May 9 at 4:32 PM
americanbankingnews.com logoTherapeuticsMD Inc (TXMD) Lowered to Market Perform at Oppenheimer Holdings Inc.
www.americanbankingnews.com - May 9 at 10:26 AM
americanbankingnews.com logoOppenheimer Holdings Inc. Reiterates Market Perform Rating for TherapeuticsMD Inc (TXMD)
www.americanbankingnews.com - May 9 at 8:36 AM
nasdaq.com logoFDA rejects TherapeuticsMD's vaginal pain drug
www.nasdaq.com - May 8 at 9:33 AM
finance.yahoo.com logoTherapeuticsMD Receives Complete Response Letter from FDA for TX-004HR New Drug Application
finance.yahoo.com - May 8 at 9:33 AM
finance.yahoo.com logoFDA rejects TherapeuticsMD's vaginal pain drug; shares slump
finance.yahoo.com - May 8 at 9:33 AM
finance.yahoo.com logoTherapeuticsMD Rejected by FDA, Delay Could be Fatal
finance.yahoo.com - May 8 at 9:33 AM
finance.yahoo.com logoIMPORTANT EQUITY ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against TherapeuticsMD, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - May 6 at 9:08 AM
finance.yahoo.com logoSHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against TherapeuticsMD, Inc. (TXMD) and Lead Plaintiff Deadline: June 19, 2017
finance.yahoo.com - May 3 at 6:40 PM
finance.yahoo.com logoIMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against TherapeuticsMD, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - May 3 at 6:40 PM
finance.yahoo.com logoThe Klein Law Firm Announces the Commencement of a Class Action Filed on Behalf of TherapeuticsMD, Inc. Shareholders and a Lead Plaintiff Deadline of June 19, 2017
finance.yahoo.com - May 3 at 6:40 PM
finance.yahoo.com logoINVESTOR ALERT: Lundin Law PC Announces a Securities Class Action Lawsuit against TherapeuticsMD, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - May 3 at 6:40 PM
finance.yahoo.com logoTherapeuticsMD Announces First Quarter 2017 Financial Results
finance.yahoo.com - May 2 at 6:25 PM
finance.yahoo.com logoTherapeuticsMD to Host TX-004HR Regulatory Update Conference Call and Webcast on May 8
finance.yahoo.com - May 2 at 6:25 PM
finance.yahoo.com logoIMPORTANT EQUITY ALERT: Lundin Law PC Announces a Securities Class Action Lawsuit against TherapeuticsMD, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - May 2 at 6:25 PM
americanbankingnews.com logoTherapeuticsMD (TXMD) Given Daily Media Sentiment Rating of 0.22
www.americanbankingnews.com - May 2 at 4:46 PM
americanbankingnews.com logoTherapeuticsMD (TXMD) Receives Coverage Optimism Score of 0.15
www.americanbankingnews.com - April 28 at 2:36 PM
finance.yahoo.com logoThe Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of TherapeuticsMD, Inc. Investors and Encourages Investors to Contact the Firm
finance.yahoo.com - April 26 at 4:53 PM

Social

Chart

TherapeuticsMD (TXMD) Chart for Friday, July, 21, 2017

This page was last updated on 7/21/2017 by MarketBeat.com Staff